MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease
November 7, 2023The World Health Organization’s (WHO) 2023 Global Tuberculosis (TB) Report released today shows that the estimated global incidence of TB in 2022 remains unacceptably high, including for the more difficult to treat form of this disease, drug-resistant TB (DR-TB). With...
Read more
MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics
July 18, 2023MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go...
Read more
TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries
July 14, 2023Christophe Perrin, TB advocacy pharmacist, MSF Access Campaign "Today's announcement by the Stop TB Partnership/Global Drug Facility about a deal with pharmaceutical corporation Johnson & Johnson (J&J), for access to affordable generic versions of the lifesaving tuberculosis (TB) drug bedaquiline, offers...
Read more
MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug
March 23, 2023Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly...
Read more
Urgent need to improve access to TB testing to support rollout of better, safer, shorter treatment for drug-resistant TB
March 22, 2023Delhi, 22 March 2023 - Médecins Sans Frontières/Doctors Without Borders (MSF) called on governments and donors today to speed up access to new, shorter, safer and more effective treatments* for drug-resistant tuberculosis (DR-TB), as well as the diagnostic tests needed...
Read more
Between life and living: Patients with drug-resistant tuberculosis (DR-TB) share stories of strength, support and suffering
December 2, 2022India has the highest burden of both tuberculosis (TB) and multi-drug resistant tuberculosis (MDR-TB) based on estimates in the WHO Global TB Report 2022. The country accounts for 28 percent of the global TB burden. In its clinic in Mumbai, MSF...
Read more
Global TB Report 2022: MSF calls for scale up of shorter and safer DR-TB treatments to help save more lives
October 28, 2022The World Health Organization (WHO) released today the 2022 edition of its Global Tuberculosis (TB) Report, featuring data on the TB response and trends in 215 countries and areas. Among the alarming trends from 2021, there is an increase in the estimated...
Read more
Fighting TB with Hope: Stories of Stigma and Strength from Three Generations in Mumbai, India
March 24, 2022From a seven-year-old child to a mother of two children, drug-resistant tuberculosis is rampant among all age groups. Globally, TB is the leading killer among infectious diseases. One-third of these deaths occurred in India. Patients either do not receive timely,...
Read more
Tuberculosis: MSF responds to updated WHO guidelines for tuberculosis in children
March 21, 2022The deadly tuberculosis diagnostic gap in children remains a major challenge Geneva – Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes the updated World Health Organization (WHO) guidelines for the management of tuberculosis (TB) in children and adolescents, which provide recommendations...
Read more
Tuberculosis: Clinical trial results offer hope to DR-TB patients with short, effective treatment
October 20, 2021LONDON – TB-PRACTECAL, a clinical trial led by Doctors Without Borders/Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) [1] than the currently accepted standard of care....
Read more
Tuberculosis: EndTB clinical trial for multidrug-resistant TB completes enrolment
October 18, 2021BOSTON/PARIS — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and...
Read more
Ukraine: Fighting tuberculosis with medication, mental health and social support
September 21, 2021In Zhytomyr, Ukraine, our teams works with the Regional TB Dispensary to treat patients who have drug-resistant forms of tuberculosis (DR-TB). They are treated with a short course of DR-TB medication and the possibility of being treated at home most of the...
Read more
